Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human VEGF receptor–antibody fusion protein
- Development stage
- Phase 1
- Lead developer
- Huabo Biopharm Co., Ltd.
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
HB-002.1 is a recombinant human VEGF receptor-antibody fusion protein developed by Huabo Biopharmaceutical, a subsidiary of Zhejiang Huahai Pharmaceutical. Designed as a biosimilar to aflibercept, it utilizes a "VEGF Trap" architecture to sequester pro-angiogenic ligands. The molecule is a dimeric glycoprotein consisting of the extracellular immunoglobulin (Ig) domain 2 of human VEGF receptor 1 (VEGFR1) and Ig domain 3 of human VEGF receptor 2 (VEGFR2), fused to the Fc portion of human IgG1. By acting as a high-affinity soluble decoy receptor, HB-002.1 binds to and neutralizes vascular endothelial growth factor A (VEGF-A), VEGF-B, and placental growth factor (PlGF). This mechanism inhibits the activation of endogenous VEGF receptors, thereby suppressing pathological angiogenesis and reducing vascular permeability. It is primarily being developed for ophthalmic conditions, specifically neovascular (wet) age-related macular degeneration (nAMD), where it is administered via intravitreal injection.
- Other names
- recombinant human VEGF receptor-antibody fusion protein injection重组人VEGF受体-抗体融合蛋白注射液重组人VEGF受体-抗体融合蛋白
02
Targets
PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on recombinant human VEGF receptor–antibody fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human VEGF receptor–antibody fusion protein.